Harmony Biosciences extends deadline for Zynerba shareholders on up to $200M deal


Harmony Biosciences entered into an agreement last month to acquire Zynerba in a deal valued at up to $200 million.

Previous OrthoLazer Louisville opens first area location
Next St. Jude completes $100M Domino's Village, grows MWBE spend